MannKind Corporation to Hold 2024 Fourth Quarter and Full Year Financial Results Conference Call on February 26, 2025
MannKind (MNKD) has announced it will release its 2024 fourth quarter and full year financial results after market close on Wednesday, February 26, 2025. The company will host a webcast at 4:30 p.m. Eastern Time to discuss the financial results and provide a business update.
The conference call will feature CEO Michael Castagna and CFO Chris Prentiss. Investors can access the webcast through MannKind's website, and a replay will be available for approximately 90 days following the call.
MannKind (MNKD) ha annunciato che rilascerà i suoi risultati finanziari del quarto trimestre e dell'intero anno 2024 dopo la chiusura del mercato mercoledì 26 febbraio 2025. L'azienda ospiterà un webcast alle 16:30 ora orientale per discutere i risultati finanziari e fornire un aggiornamento sull'attività.
La conferenza telefonica vedrà la partecipazione del CEO Michael Castagna e del CFO Chris Prentiss. Gli investitori possono accedere al webcast tramite il sito web di MannKind, e una registrazione sarà disponibile per circa 90 giorni dopo la chiamata.
MannKind (MNKD) ha anunciado que publicará sus resultados financieros del cuarto trimestre y del año completo 2024 después del cierre del mercado el miércoles 26 de febrero de 2025. La compañía llevará a cabo un webcast a las 4:30 p.m. hora del Este para discutir los resultados financieros y proporcionar una actualización del negocio.
La llamada de conferencia contará con la participación del CEO Michael Castagna y el CFO Chris Prentiss. Los inversores pueden acceder al webcast a través del sitio web de MannKind, y una grabación estará disponible durante aproximadamente 90 días después de la llamada.
MannKind (MNKD)는 2025년 2월 26일 수요일 시장 종료 후 2024년 4분기 및 연간 재무 결과를 발표할 것이라고 발표했습니다. 회사는 동부 표준시 기준 오후 4시 30분에 재무 결과를 논의하고 사업 업데이트를 제공하기 위해 웹캐스트를 진행할 예정입니다.
컨퍼런스 콜에는 CEO Michael Castagna와 CFO Chris Prentiss가 참석합니다. 투자자들은 MannKind의 웹사이트를 통해 웹캐스트에 접근할 수 있으며, 통화 후 약 90일 동안 재생이 가능할 것입니다.
MannKind (MNKD) a annoncé qu'il publiera ses résultats financiers du quatrième trimestre et de l'année 2024 après la fermeture du marché le mercredi 26 février 2025. L'entreprise organisera un webcast à 16h30, heure de l'Est, pour discuter des résultats financiers et fournir une mise à jour sur l'activité.
La conférence téléphonique mettra en vedette le PDG Michael Castagna et le CFO Chris Prentiss. Les investisseurs peuvent accéder au webcast via le site Web de MannKind, et un replay sera disponible pendant environ 90 jours après l'appel.
MannKind (MNKD) hat angekündigt, dass es seine finanziellen Ergebnisse für das vierte Quartal und das gesamte Jahr 2024 nach Marktschluss am Mittwoch, den 26. Februar 2025, veröffentlichen wird. Das Unternehmen wird um 16:30 Uhr Eastern Time ein Webcast veranstalten, um die finanziellen Ergebnisse zu besprechen und ein Update zum Geschäft zu geben.
Die Telefonkonferenz wird von CEO Michael Castagna und CFO Chris Prentiss geleitet. Investoren können auf den Webcast über die Website von MannKind zugreifen, und eine Aufzeichnung wird etwa 90 Tage nach dem Anruf verfügbar sein.
- None.
- None.
DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Feb. 19, 2025 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), will release its 2024 fourth quarter and full year financial results after market close on Wednesday, February 26, 2025.
MannKind will host a webcast beginning at 4:30 p.m. Eastern Time to discuss the financial results and provide a business update. Participating in the conference call from MannKind will be Chief Executive Officer Michael Castagna, PharmD, and Chief Financial Officer Chris Prentiss. The webcast will be accessible via a link on MannKind’s website at https://investors.mannkindcorp.com/events-and-presentations. A replay will also be available in the same location within 24 hours following the call and be accessible for approximately 90 days.
About MannKind
MannKind Corporation (Nasdaq: MNKD) focuses on the development and commercialization of innovative inhaled therapeutic products and devices to address serious unmet medical needs for those living with endocrine and orphan lung diseases.
We are committed to using our formulation capabilities and device engineering prowess to lessen the burden of diseases such as diabetes, nontuberculous mycobacterial (NTM) lung disease, pulmonary fibrosis, and pulmonary hypertension. Our signature technologies – dry-powder formulations and inhalation devices – offer rapid and convenient delivery of medicines to the deep lung where they can exert an effect locally or enter the systemic circulation, depending on the target indication.
With a passionate team of Mannitarians collaborating nationwide, we are on a mission to give people control of their health and the freedom to live life.
Please visit mannkindcorp.com to learn more, and follow us on LinkedIn, Facebook, X or Instagram.
For MannKind:
Investor Relations
Ana Kapor
(818) 661-5000
Email: ir@mnkd.com
Media Relations
Christie Iacangelo
(818) 292-3500
Email: media@mnkd.com
FAQ
When will MannKind (MNKD) release its Q4 and full-year 2024 earnings?
What time is MannKind's (MNKD) Q4 2024 earnings call?
Who will participate in MannKind's (MNKD) Q4 2024 earnings call?
How long will MannKind's (MNKD) Q4 2024 earnings call replay be available?
